Current Opinion for Diagnosis and Treatment of Merkel Cell Carcinoma

Hartschuh, Wolfgang

doi:10.1159/000218991

Cited by 1 publication

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case the scintigraphy seemed of high sensitivity, which is in accordance with a previous report. 1 …”

Section: Case Reportmentioning

confidence: 99%

“…Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine tumour of the skin, occurring mostly in elderly persons on sun‐exposed skin. 1–3 Its cell of origin is still unknown. MCC is considered as a highly malignant tumour due to its rapid growth behaviour and high frequency of local recurrence, ranging between 25 and 77% 1–6 despite local surgical (and radiation) treatment.…”

mentioning

confidence: 99%

“… 1–3 Its cell of origin is still unknown. MCC is considered as a highly malignant tumour due to its rapid growth behaviour and high frequency of local recurrence, ranging between 25 and 77% 1–6 despite local surgical (and radiation) treatment. Three‐year survival after diagnosis of visceral metastasis ranges from 30 to 60% 4,7 , 8 .…”

mentioning

confidence: 99%

“…Fenig et al . 3 and Hartschuh 1 recommended primary chemotherapy followed by local irradiation. In patients with distant metastases only short‐term remissions after chemotherapy have been reported, 1,3 leading to the current opinion that MCC is not chemosensitive.…”

mentioning

confidence: 99%

“… 3 and Hartschuh 1 recommended primary chemotherapy followed by local irradiation. In patients with distant metastases only short‐term remissions after chemotherapy have been reported, 1,3 leading to the current opinion that MCC is not chemosensitive. Commonly used chemotherapy regimens have been largely derived from the treatment of small‐cell lung cancer and consist of different combinations of doxorubicin, cyclophosphamide, 5‐fluorouracil, vincristine, methotrexate, bleomycin, etoposide, cisplatin and carboplatin.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Transient complete remission of metastasized Merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation

Waldmann¹,

Goldschmidt

Jäckel³

et al. 2000

British Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare cutaneous tumour with neuroendocrine differentiation. Metastasis occurs preferentially to regional lymph nodes but distant and multiple visceral metastases may occur. Chemotherapy has been performed with a variety of protocols based largely on agents active in small-cell lung cancer. Owing to the rarity of MCC, there is no standard protocol for the treatment of metastatic disease. We report a 59-year-old patient with systemic metastatic MCC. After diagnosis of distant metastases, first-line polychemotherapy (cisplatin 80 mg m(-2), doxorubicin 50 mg m(-2), etoposide 300 mg m(-2) and bleomycin 30 mg) was administered four times at 3-weekly intervals and resulted in partial remission of metastases. Subsequently, high-dose chemotherapy according to the PEI regimen (ifosfamide 12 g m(-2), carboplatin 900 mg m(-2) and etoposide 1500 mg m(-2)) was applied, followed by autologous blood stem cell transplantation (ABSCT). This protocol resulted in a complete remission that lasted for 6 months. This is the first report on a complete remission of metastatic MCC after high-dose polychemotherapy and ABSCT. High-dose chemotherapy might be a therapeutic option in chemosensitive metastatic MCC, and further evaluation is warranted.

show abstract

“…In this case the scintigraphy seemed of high sensitivity, which is in accordance with a previous report. 1 …”

Section: Case Reportmentioning

confidence: 99%

mentioning

confidence: 99%